1. Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa
- Author
-
Kavita Nanda, Caitlin W Scoville, Shannon L Bosman, Mags Beksinska, Jennifer A. Smit, and Ivana Beesham
- Subjects
Adult ,medicine.medical_specialty ,Randomization ,Adolescent ,Levonorgestrel ,Medroxyprogesterone Acetate ,Intrauterine device ,Sexually active ,South Africa ,Young Adult ,Contraceptive Agents, Female ,Medicine ,Medroxyprogesterone acetate ,Humans ,Contraceptive discontinuation ,business.industry ,Obstetrics ,Intrauterine Devices, Medicated ,Obstetrics and Gynecology ,Intrauterine Devices, Copper ,Discontinuation ,Contraception ,Reproductive Medicine ,Female ,Implant ,business ,medicine.drug - Abstract
Objectives : The use of intrauterine devices (IUDs) and contraceptive implants in South Africa (SA) is low with limited data on patterns of use and reasons for discontinuation. We describe contraceptive preferences and reasons for discontinuation among women enrolled in the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial from one trial site. Study Design : ECHO, conducted between 2015 and 2018, enrolled and randomized sexually active women, aged 16-35, and desiring contraception, to intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (C-IUD) or a levonorgestrel (LNG) implant; follow-up was 12-18 months. We interviewed 829 women at the Durban, SA trial site at ECHO Trial exit to ascertain contraceptive preferences at randomization. Reasons for randomized contraceptive discontinuation were collected at ECHO Trial exit and six months later. Data were analysed descriptively. Results : At the final ECHO Trial visit, among women using their randomized contraceptive method (n=757), 21% discontinued DMPA-IM, 20% discontinued LNG implant and 22% discontinued the C-IUD. About a quarter from each group discontinued due to problems with bleeding. Among women continuing their randomized contraceptive at trial exit (n=597), 25% discontinued DMPA-IM within six months of exiting the study, 8% discontinued LNG implant and 4% discontinued C-IUD. A third of women reported wanting to be assigned DMPA-IM at randomization, 20% wanted the LNG implant and 18% the C-IUD. Conclusions : Despite some women having preferences about which contraceptive they might be randomized to, discontinuation rates for all three methods at ECHO Trial exit and 6-month post-trial follow-up were low. Implications : Despite limited prior use of IUDs and implants among women enrolled in this study, and a desire by some women to not receive these methods at randomization, discontinuation rates remained low. The provision of quality contraceptive counselling and support may increase uptake and continued use of implants and IUDs.
- Published
- 2021